Top

Published in:

Open Access 01-11-2020 | Myelodysplastic Syndrome | Original Article

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation

Authors: Beatrice Drexler, Felicitas Zurbriggen, Tamara Diesch, Romaine Viollier, Joerg P. Halter, Dominik Heim, Andreas Holbro, Laura Infanti, Andreas Buser, Sabine Gerull, Michael Medinger, André Tichelli, Jakob R. Passweg

Published in: Annals of Hematology | Issue 11/2020

Abstract

Introduction

Since the 1970s outcome of aplastic anemia (AA) patients has improved significantly due to the introduction of immunosuppressive therapy (IST) and allogeneic hematopoietic transplantation (HCT). However, patients may suffer from persistent disease, relapse, clonal evolution, graft-versus-host disease and other late effects. Here, we analyse very long-term outcome of all AA patients at our institution comparing not only survival, but also response status and complications.

Methods

Patient charts of all 302 AA patients treated between 1973 and 2017 at the University Hospital Basel, Switzerland, were retrospectively analysed.

Results

First line treatment was IST in 226 (75%) and HCT in 76 (25%) patients. Overall survival at 30 years was similar in patients treated initially by HCT and IST (44% (±14%), and 40% (± 9%) respectively, with better results in more recent years. Partial and no response occurred more frequently after IST, relapse incidence after IST was 24 %, whereas non-engraftment and graft failure was documented in 15 patients (19 %) after HCT. Clonal evolution to myelodysplastic syndrome / acute myeloid leukemia was 16 % at 25 years in IST patients, 1.3 % in HCT patients, iron overload (18 versus 4 %, p = 0.002) and cardiovascular events (11 versus 1 %, p=0.011) occured significantly more often in IST than HCT treated patients. The majority of long-term survivors, 96% of those alive at 25 years, were in complete remission at last follow up, irrespective of the initial treatment modality.

Conclusion

Very long term survivors after AA are those with stable hematopoietic recovery.

Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Fuhrer M, Severe Aplastic Anemia Working Party of the European B, Marrow Transplant G (2007) Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92(1):11–18. https://doi.org/10.3324/haematol.10075CrossRefPubMed

Speck B, Gratwohl A, Nissen C, Leibundgut U, Ruggero D, Osterwalder B, Burri HP, Cornu P, Jeannet M (1981) Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) 282(6267):860–863. https://doi.org/10.1136/bmj.282.6267.860CrossRef

Townsley DM, Winkler T (2016) Nontransplant therapy for bone marrow failure. Hematol Am Soc Hematol Educ Program 2016(1):83–89. https://doi.org/10.1182/asheducation-2016.1.83CrossRef

Tichelli A, Peffault de Latour R, Passweg J, Knol-Bout C, Socie G, Marsh J, Schrezenmeier H, Hochsmann B, Bacigalupo A, Samarasinghe S, Rovo A, Kulasekararaj A, Roth A, Eikema DJ, Bosman P, Bader P, Risitano A, Dufour C, Severe Aplastic Anemia Working Party of the European Society for B, Marrow T (2019) Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globuline, cyclosporine, with or without G-CSF: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. Haematologica. 105:1223–1231. https://doi.org/10.3324/haematol.2019.222562CrossRefPubMed

Georges GE, Doney K, Storb R (2018) Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv 2(15):2020–2028. https://doi.org/10.1182/bloodadvances.2018021162CrossRefPubMedPubMedCentral

Bacigalupo A, Giammarco S, Sica S (2016) Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol 104(2):168–174. https://doi.org/10.1007/s12185-016-2037-8CrossRefPubMed

Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289(9):1130–1135. https://doi.org/10.1001/jama.289.9.1130CrossRefPubMed

Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van't Veer-Korthof E, Gluckman E (1993) Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 329(16):1152–1157. https://doi.org/10.1056/NEJM199310143291603CrossRefPubMed

Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A (2000) Late clonal diseases of treated aplastic anemia. Semin Hematol 37(1):91–101CrossRef

10.

Viollier R, Passweg J, Gregor M, Favre G, Kuhne T, Nissen C, Gratwohl A, Tichelli A (2005) Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol 84(1):47–55. https://doi.org/10.1007/s00277-004-0930-3CrossRefPubMed

11.

Camitta BM, Rappeport JM, Parkman R, Nathan DG (1975) Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 45(3):355–363CrossRef

12.

Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, Maciejewski J, Deeg J, Marsh J, Zhang FK, Lee JW, Ozawa K (2011) The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol 93(6):832–837. https://doi.org/10.1007/s12185-011-0873-0CrossRefPubMed

13.

Speck B, Gluckman E, Haak HL, van Rood JJ (1977) Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 2(8049):1145–1148. https://doi.org/10.1016/s0140-6736(77)91537-9CrossRefPubMed

14.

Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Hochsmann B, Barrois A, Champion K, Passweg JR (2011) A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 117(17):4434–4441. https://doi.org/10.1182/blood-2010-08-304071CrossRefPubMed

15.

Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS (2009) Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94(3):348–354. https://doi.org/10.3324/haematol.13829CrossRefPubMedPubMedCentral

16.

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825–828PubMed

17.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21(3):389–401 e381. https://doi.org/10.1016/j.bbmt.2014.12.001CrossRefPubMed

18.

Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study G (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101(4):1236–1242. https://doi.org/10.1182/blood-2002-04-1134CrossRefPubMed

19.

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International B, Marrow Transplant R, American Society for B, Marrow T, European Group for B, Marrow T, Asia-Pacific B, Marrow Transplantation G, Bone Marrow Transplant Society of A, New Z, East Mediterranean B, Marrow Transplantation G, Sociedade Brasileira de Transplante de Medula O (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47(3):337–341. https://doi.org/10.1038/bmt.2012.5CrossRefPubMedPubMedCentral

20.

Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB, investigators Es (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 116(14):2448–2454. https://doi.org/10.1182/blood-2010-01-261289CrossRefPubMed

21.

Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, El-Ali A, Habr D, Martin N, Porter JB (2013) Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica 98(7):1045–1048. https://doi.org/10.3324/haematol.2012.077669CrossRefPubMedPubMedCentral

22.

Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, Halter J, Meyer-Monard S, Heim D, Tsakiris DA, Biedermann B, Passweg JR, Gratwohl A (2007) Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 110(9):3463–3471. https://doi.org/10.1182/blood-2006-10-054080CrossRefPubMed

23.

Xue W, Zhang Q, Xu Y, Wang W, Zhang X, Hu X (2014) Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med J 127(12):2376–2381PubMed

24.

Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, Van Lint MT, Tichelli A, McCann S, Marsh J, Ljungman P, Hows J, Marin P, Schrezenmeier H (2000) Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol 37(1):69–80. https://doi.org/10.1016/s0037-1963(00)90031-3CrossRefPubMed

25.

Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T (2017) Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol 92(12):1295–1302. https://doi.org/10.1002/ajh.24897CrossRefPubMedPubMedCentral

26.

Vaht K, Goransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO (2017) Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica 102(10):1683–1690. https://doi.org/10.3324/haematol.2017.169862CrossRefPubMedPubMedCentral

27.

Moore MA, Castro-Malaspina H (1991) Immunosuppression in aplastic anemia--postponing the inevitable? N Engl J Med 324(19):1358–1360. https://doi.org/10.1056/NEJM199105093241909CrossRefPubMed

Title: Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
Authors: Beatrice Drexler
Felicitas Zurbriggen
Tamara Diesch
Romaine Viollier
Joerg P. Halter
Dominik Heim
Andreas Holbro
Laura Infanti
Andreas Buser
Sabine Gerull
Michael Medinger
André Tichelli
Jakob R. Passweg
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Aplastic Anemia
Anemia
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Published in: Annals of Hematology / Issue 11/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04271-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

Biallelic rare 17 bp deletion mutation (HBB:c.380_396 del TGCAGGCTGCCTATCAG) in a transfusion depended form of thalassemia

Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries

Myelomatous pleural effusion with plasmablastic morphology and high genetic complexity as isolated extramedullary relapse

Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia

Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review

Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page